Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

Anticuerpos contra la molécula-receptor de adhesión implicada en el cáncer CEACAMI1

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20151009001
Publicado:
13/10/2015
Caducidad:
12/10/2016
Resumen:
Una universidad alemana ha descubierto un anticuerpo monoclonal para la detección específica de la molécula-receptor de adhesión implicada en el cáncer CEACAMI1. La CEACAM1 forma parte de la familia (CEACAM) de moléculas de adhesión celular relacionadas al antígeno carcinoembrionario y desempeña una función esencial en la formación de nuevos vasos sanguíneos y linfáticos, en la regulación del crecimiento celular y supresión tumoral, en la metástasis de células tumorales y en la inmunomodulación. Este anticuerpo se caracteriza por su alta afinidad y monoespecificidad. Los campos de aplicación incluyen investigación, diagnóstico y monitorización terapéutica. La universidad busca licenciatarios industriales.

Details

Tittle:
Antibodies against the human cancer-implicated adhesion-receptor-molecule CEACAM1
Summary:
A German university has found a monoclonal antibody for the specific detection of the cancer-implicated adhesion-receptor-molecule CEACAM1. It is characterized by high affinity and mono-specificity. Fields of application are in research, diagnostics and therapy monitoring. Industrial licensees are sought.
Description:
CEACAM1 is a member of the carcinoembryonic antigen related cell adhesion molecule (CEACAM)-family. The transmembrane glycoprotein is expressed on leukocytes, epithelium and endothelium cells.

CEACAM1 plays a central role in following:
· the formation of new blood and lymphatic vessels,
· the regulation of cell growth, tumor suppression,
· the metastasis formation of tumor cells
· as well as in immunomodulation.

CEACAMs are structurally closely related: they feature the function triggering N-domain and a C-domain consisting of A- and B-domains. Due to the structural similarity it is very challenging to obtain antibodies against specific CEACAM1-domains. CEACAM1 has been detected at elevated levels in the surrounding tissue of tumors and the tumors themselves. It appears that CEACAM1 is a suitable biomarker for the diagnosis and staging of tumors.

The present invention of a German university relates to an antibody that exhibits a high affinity and mono-specificity for the A1/B-domains of human CEACAM1. Thus, it is suitable to detect the membrane anchored, the cleaved soluble CEACAM1 and most of its derivatives.

This antibody is of use in several research applications, including enzyme-linked immunosorbent assays (ELISA), immunoprecipitation (IP), immunohistochemistry (IHC), fluorescence microscopy and flow cytometry. In addition, the monoclonal antibody (mAB) is suitable for use as a diagnostic tool for the detection of inflammatory disorders (e.g. sepsis, multiple sclerosis) as well as for solid tumors, and applies for therapy monitoring of the latter.

Licensees are sought to implement the antibody in any of the above applications. Potential partners are from pharmaceutical industry active in cancer research and diagnostics.

Advantages and Innovations:
New invention:
· Monoclonal antibody directed against the A1/B-domains of human CEACAM1
· High affinity and mono-specificity
· Detects membrane anchored and soluble human CEACAM1 and most of its derivatives
· Suitable for numerous applications:
- in cancer research
- in diagnosis
- in therapy monitoring
- as immune-modulator in the therapy of tumors, infections and inflammations
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
A German patent application has been filed.

Partner sought

Type and Role of Partner Sought:
Licensees from pharmaceutical industry are sought, who are interested in commercial use of the antibody in research, diagnostics and / or therapeutic applications.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German

Keywords

Technology Keywords:
06001003 Citología, cancerología, oncología
06001005 Diagnósticos, diagnosis
06001015 Productos farmacéuticos / medicamentos